UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences

Clinical pharmacokinetics, 2020-02, Vol.59 (2), p.155-172

2020

Volltextzugriff (PDF)

Heart rate dynamics during cardio-pulmonary exercise testing are associated with glycemic control in individuals with type 1 diabetes

PloS one, 2018-04, Vol.13 (4), p.e0194750-e0194750

2018

Volltextzugriff (PDF)

A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance

Clinical pharmacokinetics, 2014-09, Vol.53 (9), p.787-800

2014

Volltextzugriff (PDF)

Effects of hypoglycaemia on working memory and regional cerebral blood flow in type 1 diabetes: a randomised, crossover trial

Diabetologia, 2018-03, Vol.61 (3), p.551-561

2018

Volltextzugriff (PDF)

A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes

Clinical pharmacokinetics, 2017-05, Vol.56 (5), p.551-559

2017

Volltextzugriff (PDF)

A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use

Clinical pharmacokinetics, 2017-04, Vol.56 (4), p.339-354

2017

Volltextzugriff (PDF)

Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus

Clinical pharmacokinetics, 2017-06, Vol.56 (6), p.649-660

2017

Volltextzugriff (PDF)

Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial

Diabetologia, 2023-08, Vol.66 (8), p.1413-1430

2023

Volltextzugriff (PDF)

Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment

Clinical pharmacokinetics, 2014-02, Vol.53 (2), p.175-183

2014

Volltextzugriff (PDF)

A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus

Drugs & aging, 2017-01, Vol.34 (1), p.29-38

2017

Volltextzugriff (PDF)

Pharmacokinetic and Pharmacodynamic Characteristics of Insulin Icodec After Subcutaneous Administration in the Thigh, Abdomen or Upper Arm in Individuals with Type 2 Diabetes Mellitus

Clinical drug investigation, 2023-02, Vol.43 (2), p.119-127

2023

Volltextzugriff (PDF)

Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus

Clinical pharmacokinetics, 2019-05, Vol.58 (5), p.639-649

2019

Volltextzugriff (PDF)

Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions

Clinical drug investigation, 2017-05, Vol.37 (5), p.503-509

2017

Volltextzugriff (PDF)

The Effect of Various Degrees of Renal or Hepatic Impairment on the Pharmacokinetic Properties of Once-Weekly Insulin Icodec

Clinical pharmacokinetics, 2024-06, Vol.63 (6), p.819-830

2024

Volltextzugriff (PDF)

The Distinct Prandial and Basal Pharmacodynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 Diabetes

Drugs & aging, 2015-07, Vol.32 (7), p.583-590

2015

Volltextzugriff (PDF)

Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus

Diabetes therapy, 2014-06, Vol.5 (1), p.255-265

2014

Volltextzugriff (PDF)

Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study

Diabetologia, 2014-01, Vol.57 (1), p.40-49

2014

Volltextzugriff (PDF)

A Comparison of the Steady-State Pharmacokinetic and Pharmacodynamic Profiles of 100 and 200 U/mL Formulations of Ultra-Long-Acting Insulin Degludec

Clinical drug investigation, 2013-07, Vol.33 (7), p.515-521

2013

Volltextzugriff (PDF)

Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment

Clinical drug investigation, 2014-02, Vol.34 (2), p.127-133

2014

Volltextzugriff (PDF)

Pharmacokinetic Properties of Fast-acting Insulin Aspart Administered in Different Subcutaneous Injection Regions: Response to the commentary by Nuggehally R. Srinivas

Clinical drug investigation, 2017-09, Vol.37 (9), p.885-887

2017

Volltextzugriff (PDF)

Glucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region

Clinical drug investigation, 2014-09, Vol.34 (9), p.673-679

2014

Volltextzugriff (PDF)

4. Earlier Onset and Higher Early Exposure of Faster- Acting Insulin Aspart vs. Insulin Aspart in Adults Is Retained in Children and Adolescents with T1D (976-P)

Nederlands Tijdschrift voor Diabetolog, 2015-09, Vol.13 (3), p.57-58

2015

Volltextzugriff (PDF)

Caregiver distress in first-episode psychosis: the role of subjective appraisal, over-involvement and symptomatology

Social Psychiatry and Psychiatric Epidemiology, 2015-03, Vol.50 (3), p.371-378

2015

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Aktive Filter

ThemaMedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(23)

Sprache

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences

Heart rate dynamics during cardio-pulmonary exercise testing are associated with glycemic control in individuals with type 1 diabetes

A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance

Effects of hypoglycaemia on working memory and regional cerebral blood flow in type 1 diabetes: a randomised, crossover trial

A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes

A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use

Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus

Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial

Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment

A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus

Pharmacokinetic and Pharmacodynamic Characteristics of Insulin Icodec After Subcutaneous Administration in the Thigh, Abdomen or Upper Arm in Individuals with Type 2 Diabetes Mellitus

Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus

Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions

The Effect of Various Degrees of Renal or Hepatic Impairment on the Pharmacokinetic Properties of Once-Weekly Insulin Icodec

The Distinct Prandial and Basal Pharmacodynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 Diabetes

Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus

Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study

A Comparison of the Steady-State Pharmacokinetic and Pharmacodynamic Profiles of 100 and 200 U/mL Formulations of Ultra-Long-Acting Insulin Degludec

Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment

Pharmacokinetic Properties of Fast-acting Insulin Aspart Administered in Different Subcutaneous Injection Regions: Response to the commentary by Nuggehally R. Srinivas

Glucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region

4. Earlier Onset and Higher Early Exposure of Faster- Acting Insulin Aspart vs. Insulin Aspart in Adults Is Retained in Children and Adolescents with T1D (976-P)

Caregiver distress in first-episode psychosis: the role of subjective appraisal, over-involvement and symptomatology

Aktive Filter

Suchergebnisse filtern